产品说明书

Ataluren

Print
Chemical Structure| 775304-57-9 同义名 : PTC124
CAS号 : 775304-57-9
货号 : A306827
分子式 : C15H9FN2O3
纯度 : 98%
分子量 : 284.242
MDL号 : MFCD09864996
存储条件:

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(175.91 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:

IP 4% DMSO+2% Tween80+40% PEG300+water 1 mg/mL clear

PO 0.5% CMC-Na 22 mg/mL suspension

生物活性
靶点
  • CFTR

描述 Nonsense mutations have been implicated in numerous inherited diseases and several cancers. For example, cystic fibrosis (CF) is a common autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. PTC-124 is an orally bioavailable compound that promotes readthrough of premature translation termination codons, suggesting its potential to treat genetic diseases caused by nonsense mutations like mutations in CFTR[3]. The minimal concentration of PTC-124 showing discernable readthrough was 0.01–0.1 μM (2.8-28 ng/ml). And it promoted dose-dependent readthrough of all three nonsense codons in stable cell lines harbouring LUC-190 nonsense alleles[4]. In a mouse model with CF, s.c. injection or oral administration of PTC-124 (60 mg/kg) to Cftr-/- mice expressing a human CFTR-G542X transgene suppressed the G542X nonsense mutation and restored a significant amount of human (h)CFTR protein and function. In addition, PTC-124 (60 mg/kg by s.c. injection or a liquid diet containing 0.9 mg/ml PTC-124) treatment restored 24-29% of the average cAMP-stimulated transepithelial chloride currents observed in wild-type mice. These results indicate that PTC-124 can effectively suppress the hCFTR-G542X nonsense mutation in vivo[3].
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
BAC_MMA∗EGFP 20 μM Function Assay 72 h  results in a significant increase in median peak fluorescence 23041189
HEK293T 10 µg/ml Function Assay restores full-length harmonin a1 (∼80 kDa) in p.R31X-transfected cells 23027640
ML1 3.3/10 μM Function Assay 48 h increases ARSB activity 22971959
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03256799 Cystic Fibrosis Phase 4 Completed - United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 收起 <<
NCT02139306 Cystic Fibrosis Phase 3 Unknown November 2016 -
NCT01182324 - Completed - United States, Maryland ... 展开 >> National Human Genome Research Institute (NHGRI), 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.52mL

0.70mL

0.35mL

17.59mL

3.52mL

1.76mL

35.18mL

7.04mL

3.52mL

参考文献

[1]105(6):2064-9

[2]447(7140):87-91